Get the Stockscreener App
23.04
6.04%
-1.48
Monte Rosa Therapeutics Inc stock is traded at $23.04, with a volume of 1.72M.
It is down -6.04% in the last 24 hours and up +39.47% over the past month.
Monte Rosa Therapeutics Inc is a clinical-stage biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. The company has three programs in clinical development: MRT-6160, a VAV1-directed MGD for immune-mediated diseases; MRT-8102, a NEK7-directed MGD for inflammatory diseases driven by IL-6, and the NLRP3 inflammasome; and MRT-2359, a GSPT1-directed MGD for metastatic castration resistant prostate cancer (mCRPC).
See More
Previous Close:
$24.52
Open:
$24.17
24h Volume:
1.72M
Relative Volume:
1.54
Market Cap:
$1.95B
Revenue:
$42.95M
Net Income/Loss:
$-130.01M
P/E Ratio:
-14.15
EPS:
-1.6278
Net Cash Flow:
$-19.66M
1W Performance:
-4.83%
1M Performance:
+39.47%
6M Performance:
-5.11%
1Y Performance:
+338.02%
1-Day Range:
$22.30
$24.17
1-Week Range:
$22.30
$24.98
52-Week Range:
$4.12
$25.77
Monte Rosa Therapeutics Inc Stock (GLUE) Company Profile
Name
Monte Rosa Therapeutics Inc
Sector
Industry
Phone
617-949-2643
Address
321 HARRISON AVENUE, BOSTON
Compare GLUE vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GLUE
Monte Rosa Therapeutics Inc
|
23.04 | 1.95B | 42.95M | -130.01M | -19.66M | -1.6278 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Monte Rosa Therapeutics Inc Stock (GLUE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-19-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Feb-15-24 | Initiated | Wedbush | Outperform |
| Jan-03-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Oct-13-22 | Initiated | UBS | Buy |
| Aug-15-22 | Initiated | Jefferies | Buy |
| Apr-28-22 | Initiated | Credit Suisse | Neutral |
| Feb-10-22 | Initiated | Wells Fargo | Equal Weight |
| Oct-14-21 | Initiated | SVB Leerink | Mkt Perform |
View All
Monte Rosa Therapeutics Inc Stock (GLUE) Latest News
Monte Rosa Therapeutics (NASDAQ:GLUE) Stock Price Down 8.7%Here's What Happened - MarketBeat
Monte Rosa Therapeutics (GLUE) Recast As A Growth Name As Valuation Questions Build - simplywall.st
T. Rowe Price reports 8.86M-share stake in Monte Rosa Therapeutics (GLUE) - Stock Titan
Monte Rosa Therapeutics CSO Sharon Townson sells shares worth $139,849 - Investing.com
Form 4 Monte Rosa Therapeutics Inc For: 7 July By Investing.com - Investing.com Canada
Monte Rosa Therapeutics CSO Sharon Townson sells shares worth $139,849 By Investing.com - Investing.com Canada
Monte Rosa Therapeutics (GLUE) CSO sells 6,000 shares after option exercise - Stock Titan
Monte Rosa Therapeutics (NASDAQ:GLUE) Trading Up 6.9%Should You Buy? - MarketBeat
AUPH Stock Price and Chart — NASDAQ:AUPH - TradingView
Form 4 Monte Rosa Therapeutics Inc For: 6 July By Investing.com - Investing.com Nigeria
Form 13D/A Monte Rosa Therapeutics For: 6 July By Investing.com - Investing.com Canada
NEA funds shift 1,000,000 Monte Rosa shares (NASDAQ: GLUE) - Stock Titan
NEA adjusts Monte Rosa Therapeutics (GLUE) stake with share distribution and sales - Stock Titan
GLUEMonte Rosa Therapeutics Inc Volatility & Greeks - Finviz
Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Monte Rosa lures 3 new hires with stock awards worth 18,025 options - Stock Titan
Form 4 Monte Rosa Therapeutics Inc For: 1 July By Investing.com - Investing.com Nigeria
Monte Rosa CMO Filip Janku sells $132k in company stock - Investing.com
Filip Janku Sells 5,407 Shares of Monte Rosa Therapeutics (NASDAQ:GLUE) Stock - MarketBeat
Monte Rosa Therapeutics (NASDAQ: GLUE) CMO trades 5,407 shares under 10b5-1 plan - Stock Titan
Form 144 Monte Rosa Therapeutics For: 30 June By Investing.com - Investing.com Australia
Form 4 Monte Rosa Therapeutics Inc For: 30 June By Investing.com - Investing.com South Africa
Monte Rosa director Anthony Manning sells $231,100 in GLUE shares By Investing.com - Investing.com Nigeria
Monte Rosa director Anthony Manning sells $231,100 in GLUE shares - Investing.com
GLUE (NASDAQ: GLUE) affiliate reports option exercise and 10b5-1 sales in June 2026 - Stock Titan
Monte Rosa Therapeutics | 144: Notice of proposed sale of securities pursuant to Rule 144 - Moomoo
Monte Rosa (NASDAQ: GLUE) CMO exercises options, sells 6,000 shares - Stock Titan
Monte Rosa (NASDAQ: GLUE) director exercises options, sells 10,000 shares at $23.11 - Stock Titan
Guggenheim raises Monte Rosa stock price target on pipeline potential - Investing.com UK
Guggenheim raises Monte Rosa stock price target on pipeline potential By Investing.com - Investing.com South Africa
symbol__ Stock Quote Price and Forecast - CNN
After a 400% Surge, Should Investors Care About This $882,000 Monte Rosa Insider Sale? - The Motley Fool
GLUE (NASDAQ: GLUE) option exercise; insider 10b5-1 sales total 41,845 shares - Stock Titan
Anthony Manning sells 10,000 GLUE shares; option exercise planned (GLUE) - Stock Titan
Monte Rosa Therapeutics, Inc.(NasdaqGS:GLUE) added to Russell 2500 Growth Benchmark - marketscreener.com
Monte Rosa Therapeutics, Inc.(NasdaqGS:GLUE) dropped from Russell Microcap Value Benchmark Index - marketscreener.com
Monte Rosa Therapeutics, Inc.(NasdaqGS:GLUE) dropped from Russell 2000 Value Benchmark - marketscreener.com
Monte Rosa Therapeutics, Inc.(NasdaqGS:GLUE) added to Russell Microcap Growth Benchmark Index - marketscreener.com
Monte Rosa Therapeutics, Inc.(NasdaqGS:GLUE) added to Russell 2000 Growth Benchmark - marketscreener.com
Monte Rosa Therapeutics, Inc.(NasdaqGS:GLUE) added to Russell 3000E Growth Benchmark - marketscreener.com
Does Monte Rosa Therapeutics' (GLUE) Shift Into Russell Growth Indices Recast Its Biotech Risk Profile? - simplywall.st
Monte Rosa Therapeutics, Inc.(NasdaqGS:GLUE) dropped from Russell 3000E Value Benchmark - marketscreener.com
Monte Rosa Therapeutics, Inc.(NasdaqGS:GLUE) added to Russell Small Cap Comp Growth Benchmark - marketscreener.com
Monte Rosa Therapeutics, Inc. Actuals & Estimates (NASDAQ:GLUE) - TradingView
Monte Rosa (GLUE) CMO sells 41,845 shares after exercising options - Stock Titan
Monte Rosa (NASDAQ: GLUE) COO exercises stock options, sells 2,175 shares - Stock Titan
GLUE Forecast — Price Target — Prediction for 2027 - TradingView
Insider exercises 30,000 shares; sells 11,845 under 10b5-1 (GLUE) - Stock Titan
Wells Fargo Maintains Monte Rosa Therapeutics(GLUE.US) With Buy Rating, Maintains Target Price $29 - Moomoo
Monte Rosa Therapeutics Inc Stock (GLUE) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.64%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):